{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T10:40:09Z","timestamp":1747651209451,"version":"3.40.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12325-015-0182-8","type":"journal-article","created":{"date-parts":[[2015,2,17]],"date-time":"2015-02-17T09:44:55Z","timestamp":1424166295000},"page":"120-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Ivabradine in Combination with Beta-Blockers in Patients with Chronic Stable Angina After Percutaneous Coronary Intervention"],"prefix":"10.1007","volume":"32","author":[{"given":"Karl","family":"Werdan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Ebelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Nuding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"H\u00f6pfner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"M\u00fcller-Werdan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,17]]},"reference":[{"key":"182_CR1","unstructured":"World Health Organization. Types of cardiovascular disease. 2014. Available from: http:\/\/www.who.int\/cardiovascular_diseases\/en\/cvd_atlas_01_types.pdf?ua=1 . Accessed July 31, 2014."},{"issue":"38","key":"182_CR2","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949\u20133003.","journal-title":"Eur Heart J"},{"issue":"25","key":"182_CR3","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1161\/CIR.0b013e318277d6a0","volume":"126","author":"SD Fihn","year":"2012","unstructured":"Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):e354\u2013471.","journal-title":"Circulation"},{"issue":"22","key":"182_CR4","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/eurheartj\/ehs289","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, Greenlaw N, Tardif JC, et al. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. Eur Heart J. 2012;33(22):2831\u201340.","journal-title":"Eur Heart J"},{"key":"182_CR5","doi-asserted-by":"crossref","unstructured":"Ferrari R, Ford I, Greenlaw N, et al. Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: data from the contemporary CLARIFY registry. Eur J Prev Cardiol. 2014. Epub ahead of print.","DOI":"10.1177\/2047487314547652"},{"issue":"9859","key":"182_CR6","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","volume":"380","author":"T Vos","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163\u201396.","journal-title":"Lancet"},{"key":"182_CR7","doi-asserted-by":"crossref","unstructured":"Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants. Lancet. 1997;350(9076):461\u20138.","DOI":"10.1016\/S0140-6736(97)07298-X"},{"issue":"7","key":"182_CR8","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0735-1097(03)00951-3","volume":"42","author":"RA Henderson","year":"2003","unstructured":"Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol. 2003;42(7):1161\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"182_CR9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJM199201023260102","volume":"326","author":"AF Parisi","year":"1992","unstructured":"Parisi AF, Folland ED, Hartigan P. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators. N Engl J Med. 1992;326(1):10\u20136.","journal-title":"N Engl J Med"},{"issue":"7","key":"182_CR10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1056\/NEJMoa072771","volume":"359","author":"WS Weintraub","year":"2008","unstructured":"Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med. 2008;359(7):677\u201387.","journal-title":"N Engl J Med"},{"issue":"5","key":"182_CR11","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1067\/mhj.2002.125505","volume":"144","author":"R Holubkov","year":"2002","unstructured":"Holubkov R, Laskey WK, Haviland A, et al. Angina 1\u00a0year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J. 2002;144(5):826\u201333.","journal-title":"Am Heart J"},{"issue":"2","key":"182_CR12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/heart.87.2.140","volume":"87","author":"B Brorsson","year":"2002","unstructured":"Brorsson B, Bernstein SJ, Brook RH, Werko L. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart. 2002;87(2):140\u20135.","journal-title":"Heart"},{"issue":"12","key":"182_CR13","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/archinte.168.12.1310","volume":"168","author":"TM Maddox","year":"2008","unstructured":"Maddox TM, Reid KJ, Spertus JA, et al. Angina at 1\u00a0year after myocardial infarction: prevalence and associated findings. Arch Intern Med. 2008;168(12):1310\u20136.","journal-title":"Arch Intern Med"},{"issue":"15","key":"182_CR14","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"WE Boden","year":"2007","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503\u201316.","journal-title":"N Engl J Med"},{"issue":"4","key":"182_CR15","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1161\/CIRCINTERVENTIONS.112.970954","volume":"5","author":"S Pursnani","year":"2012","unstructured":"Pursnani S, Korley F, Gopaul R, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv. 2012;5(4):476\u201390.","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"182_CR16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archinternmed.2011.1484","volume":"172","author":"K Stergiopoulos","year":"2012","unstructured":"Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(4):312\u20139.","journal-title":"Arch Intern Med"},{"issue":"13","key":"182_CR17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1056\/NEJMoa1408758","volume":"371","author":"B Bruyne De","year":"2014","unstructured":"De Bruyne B, Fearon WF, Pijls NH, et al. Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med. 2014;371(13):1208\u201317.","journal-title":"N Engl J Med"},{"issue":"18","key":"182_CR18","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.2011.601","volume":"305","author":"WB Borden","year":"2011","unstructured":"Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA. 2011;305(18):1882\u20139.","journal-title":"JAMA"},{"key":"182_CR19","unstructured":"Summary of product characteristics. Procoralan. European Medicines Agency. 2005. Available from: http:\/\/www.ema.europa.eu . Accessed 15 April 2014."},{"issue":"6","key":"182_CR20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","volume":"107","author":"JS Borer","year":"2003","unstructured":"Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817\u201323.","journal-title":"Circulation"},{"issue":"23","key":"182_CR21","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"JC Tardif","year":"2005","unstructured":"Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529\u201336.","journal-title":"Eur Heart J"},{"issue":"3","key":"182_CR22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00003495-200767030-00005","volume":"67","author":"W Ruzyllo","year":"2007","unstructured":"Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs. 2007;67(3):393\u2013405.","journal-title":"Drugs."},{"issue":"10","key":"182_CR23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00392-010-0172-4","volume":"99","author":"R Koester","year":"2010","unstructured":"Koester R, Kaehler J, Ebelt H, Soeffker G, Werdan K, Meinertz T. Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol. 2010;99(10):665\u201372.","journal-title":"Clin Res Cardiol."},{"issue":"5","key":"182_CR24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00392-011-0402-4","volume":"101","author":"K Werdan","year":"2012","unstructured":"Werdan K, Ebelt H, Nuding S, Hopfner F, Hack G, Muller-Werdan U. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012;101(5):365\u201373.","journal-title":"Clin Res Cardiol."},{"issue":"11","key":"182_CR25","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095\u2013108.","journal-title":"Med Care"},{"issue":"2","key":"182_CR26","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000219938","volume":"114","author":"M Tendera","year":"2009","unstructured":"Tendera M, Borer J, Tardif J. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris. Cardiology. 2009;114(2):116\u201325.","journal-title":"Cardiology"},{"issue":"1","key":"182_CR27","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcin.2007.10.001","volume":"1","author":"DR Holmes Jr","year":"2008","unstructured":"Holmes DR Jr, Gersh BJ, Whitlow P, King SB III, Dove JT. Percutaneous coronary intervention for chronic stable angina: a reassessment. JACC Cardiovasc Interv. 2008;1(1):34\u201343.","journal-title":"JACC Cardiovasc Interv"},{"issue":"24","key":"182_CR28","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1056\/NEJMcp042317","volume":"352","author":"J Abrams","year":"2005","unstructured":"Abrams J. Clinical practice. Chronic stable angina. N Engl J Med. 2005;352(24):2524\u201333.","journal-title":"N Engl J Med"},{"issue":"9667","key":"182_CR29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(09)60319-6","volume":"373","author":"TA Trikalinos","year":"2009","unstructured":"Trikalinos TA, Sheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and a network meta-analysis. Lancet. 2009;373(9667):911\u20138.","journal-title":"Lancet"},{"issue":"17","key":"182_CR30","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMe1103414","volume":"364","author":"JC Fang","year":"2011","unstructured":"Fang JC. Underestimating medical therapy for coronary disease\u2026 again. N Engl J Med. 2011;364(17):1671\u20133.","journal-title":"N Engl J Med"},{"issue":"7","key":"182_CR31","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrcardio.2011.58","volume":"8","author":"KM Fox","year":"2011","unstructured":"Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol. 2011;8(7):369\u201379.","journal-title":"Nat Rev Cardiol"},{"issue":"16","key":"182_CR32","doi-asserted-by":"crossref","first-page":"19F","DOI":"10.1016\/0002-9149(92)90185-2","volume":"70","author":"PC Deedwania","year":"1992","unstructured":"Deedwania PC, Carbajal EV. Role of myocardial oxygen demand in the pathogenesis of silent ischemia during daily life. Am J Cardiol. 1992;70(16):19F\u201324F.","journal-title":"Am J Cardiol"},{"issue":"2","key":"182_CR33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0735-1097(91)90593-X","volume":"18","author":"A Hinderliter","year":"1991","unstructured":"Hinderliter A, Miller P, Bragdon E, Ballenger M, Sheps D. Myocardial ischemia during daily activities: the importance of increased myocardial oxygen demand. J Am Coll Cardiol. 1991;18(2):405\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"182_CR34","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1161\/01.CIR.83.4.1263","volume":"83","author":"JM McLenachan","year":"1991","unstructured":"McLenachan JM, Weidinger FF, Barry J, et al. Relations between heart rate, ischemia, and drug therapy during daily life in patients with coronary artery disease. Circulation. 1991;83(4):1263\u201370.","journal-title":"Circulation"},{"issue":"1014","key":"182_CR35","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/pgmj.2009.084384","volume":"86","author":"CA Daly","year":"2010","unstructured":"Daly CA, Clemens F, Sendon JL, et al. Inadequate control of heart rate in patients with stable angina: results from the European heart survey. Postgrad Med J. 2010;86(1014):212\u20137.","journal-title":"Postgrad Med J"},{"issue":"2","key":"182_CR36","doi-asserted-by":"crossref","first-page":"H676","DOI":"10.1152\/ajpheart.00564.2002","volume":"284","author":"P Colin","year":"2003","unstructured":"Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol. 2003;284(2):H676\u201382.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"182_CR37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0022-3565(25)12114-9","volume":"275","author":"L Simon","year":"1995","unstructured":"Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275(2):659\u201366.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"182_CR38","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/heartjnl-2013-304880","volume":"100","author":"S Gloekler","year":"2014","unstructured":"Gloekler S, Traupe T, Stoller M, et al. The effect of heart rate reduction by ivabradine on collateral function in patients with chronic stable coronary artery disease. Heart. 2014;100(2):160\u20136.","journal-title":"Heart"},{"issue":"8","key":"182_CR39","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/sj.bjp.0707673","volume":"153","author":"G Heusch","year":"2008","unstructured":"Heusch G. Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents. Br J Pharmacol. 2008;153(8):1589\u2013601.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"182_CR40","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","volume":"30","author":"JC Tardif","year":"2009","unstructured":"Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4\u00a0month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540\u20138.","journal-title":"Eur Heart J"},{"issue":"5","key":"182_CR41","doi-asserted-by":"crossref","first-page":"e36284","DOI":"10.1371\/journal.pone.0036284","volume":"7","author":"PG Steg","year":"2012","unstructured":"Steg PG, Ferrari R, Ford I, et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One. 2012;7(5):e36284.","journal-title":"PLoS One"},{"issue":"5","key":"182_CR42","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MJT.0b013e3181758855","volume":"15","author":"JS Borer","year":"2008","unstructured":"Borer JS, Heuzey JY. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther. 2008;15(5):461\u201373.","journal-title":"Am J Ther"},{"issue":"6","key":"182_CR43","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/0003319711399897","volume":"62","author":"AW Gardner","year":"2011","unstructured":"Gardner AW, Montgomery PS, Ritti-Dias RM, Thadani U. Exercise performance, physical activity, and health-related quality of life in participants with stable angina. Angiology. 2011;62(6):461\u20136.","journal-title":"Angiology"},{"issue":"16","key":"182_CR44","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1001\/archinternmed.2009.295","volume":"169","author":"JF Beltrame","year":"2009","unstructured":"Beltrame JF, Weekes AJ, Morgan C, Tavella R, Spertus JA. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: the Coronary Artery Disease in General Practice (CADENCE) Study. Arch Intern Med. 2009;169(16):1491\u20139.","journal-title":"Arch Intern Med"},{"issue":"2","key":"182_CR45","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ccd.24376","volume":"81","author":"JC Blankenship","year":"2013","unstructured":"Blankenship JC, Marshall JJ, Pinto DS, et al. Effect of percutaneous coronary intervention on quality of life: a consensus statement from the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv. 2013;81(2):243\u201359.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"12","key":"182_CR46","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","volume":"371","author":"K Fox","year":"2014","unstructured":"Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091\u20139.","journal-title":"N Engl J Med"},{"key":"182_CR47","unstructured":"European Medicines Agency recommends measures to reduced the risk of heart problems with Corlentor\/Procoralan (ivabradine. EMA: London, UK. 2014. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2014\/11\/news_detail_002207.jsp&mid=WC0b01ac058004d5c1 . Accessed December 5, 2014."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0182-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T10:12:32Z","timestamp":1747649552000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-015-0182-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["182"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0182-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}